Value proposition

Abzu is the best in class in silico disease understanding and drug design company.

Abzu is the best in class in silico disease understanding and drug design company. Since its founding in 2018, Abzu’s proprietary explainable AI, the QLattice®, has been the cornerstone to their cutting-edge approach. Abzu is a preferred partner for pharma, biotech, and research institutions, transforming data into insights and accelerating R&D.

Abzu has offices in Copenhagen and Barcelona, and has raised €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to Cool VendorTM, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards.

RNA Therapeutics, RNA Tx, AI, artificial intelligence, explainable AI, trustworthy AI, QLattice, drug development, pharma, and pharma R&D